Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols

Genes Chromosomes and Cancer

Volumn 53, Issue 11, 2014, Pages 911-916

  Rohde, Marius ^a   Richter, Julia ^b   Schlesner, Matthias ^c   Betts, Matthew J ^d   Claviez, Alexander ^e   Bonn, Bettina R ^f   Zimmermann, Martin ^a   Damm Welk, Christine ^a   Russell, Robert B ^d   Borkhardt, Arndt ^g   Eils, Roland ^c,d   Hoell, Jessica I ^g   Szczepanowski, Monika ^b   Oschlies, Ilske ^b   Klapper, Wolfram ^b   Burkhardt, Birgit ^a,f   Siebert, Reiner ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; PREDNISONE; RHOA PROTEIN, HUMAN; VINCRISTINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BURKITT LYMPHOMA; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; COHORT ANALYSIS; EVENT FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; GERMLINE MUTATION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SOMATIC MUTATION; GENETICS; LYMPHOMA, B-CELL; METABOLISM; MUTATION; PATHOLOGY; PEDIATRICS; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DAUNORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MUTATION; PEDIATRICS; PREDNISONE; RHOA GTP-BINDING PROTEIN; VINCRISTINE;

EID: 84927579211     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22202     Document Type: Article

References (34)

1. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A, Group BFM. 2005. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 131:39-49.
2. Carracedo A, Pandolfi PP. 2008. The PTEN-PI3K pathway: Of feedbacks and cross-talks. Oncogene 27:5527-5541.
3. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project. 2006. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442.
4. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M. 2012. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481:90-93.
5. Dvorsky R, Ahmadian MR. 2004. Always look on the bright site of Rho: Structural implications for a conserved intermolecular interface. EMBO Rep 5:1130-1136.
6. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kuhn M, Lenze D, Lichter P, Martin-Subero JI, Moller P, Muller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Sturzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trumper L, Stein H, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche K. 2006. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430.
7. Johnston JM, Carroll WL. 1992. c-myc hypermutation in Burkitt's lymphoma. Leuk Lymphoma 8:431-439.
8. Klapproth K, Wirth T. 2010. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 149:484-497.
9. Kristelly R, Gao G, Tesmer JJ. 2004. Structural determinants of RhoA binding and nucleotide exchange in leukemia-associated Rho guanine-nucleotide exchange factor. J Biol Chem 279:47352-47362.
10. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. 2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501.
11. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. 2012. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44:1321-1325.
12. Lutz S, Shankaranarayanan A, Coco C, Ridilla M, Nance MR, Vettel C, Baltus D, Evelyn CR, Neubig RR, Wieland T, Tesmer JJ. 2007. Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science 318:1923-1927.
13. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA. 2014. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-170.
14. Papakonstanti EA, Ridley AJ, Vanhaesebroeck B. 2007. The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J 26:3050-3061.
15. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Moller P, MacLeod RA, Pott C, Schreiber S, Trumper L, Loeffler M, Stadler PF, Lichter P, Eils R, Kuppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R, Project IM-S. 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44:1316-1320.
16. Ridley AJ. 2013. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc 251:242-249.
17. Roschke V, Kopantzev E, Dertzbaugh M, Rudikoff S. 1997. Chromosomal translocations deregulating c-myc are associated with normal immune responses. Oncogene 14:3011-3016.
18. Rose R, Weyand M, Lammers M, Ishizaki T, Ahmadian MR, Wittinghofer A. 2005. Structural and mechanistic insights into the interaction between Rho and mammalian Dia. Nature 435:513-518.
19. Rossman KL, Der CJ, Sondek J. 2005. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6:167-180.
20. Saci A, Carpenter CL. 2005. RhoA GTPase regulates B cell receptor signaling. Mol Cell 17:205-214.
21. Sahai E, Alberts AS, Treisman R. 1998. RhoA effector mutants reveal distinct effector pathways for cytoskeletal reorganization, SRF activation and transformation. EMBO J 17:1350-1361.
22. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S. 2014. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46:171-175.
23. Sander S, Calado DP, Srinivasan L, Kochert K, Zhang B, Rosolowski M, Rodig SJ, Holzmann K, Stilgenbauer S, Siebert R, Bullinger L, Rajewsky K. 2012. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22:167-179.
24. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116-120.
25. Snyder JT, Worthylake DK, Rossman KL, Betts L, Pruitt WM, Siderovski DP, Der CJ, Sondek J. 2002. Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. Nat Struct Biol 9:468-475.
26. Tnimov Z, Guo Z, Gambin Y, Nguyen UT, Wu YW, Abankwa D, Stigter A, Collins BM, Waldmann H, Goody RS, Alexandrov K. 2012. Quantitative analysis of prenylated RhoA interaction with its chaperone, RhoGDI. J Biol Chem 287:26549-26562.
27. Vetter IR, Wittinghofer A. 2001. The guanine nucleotide-binding switch in three dimensions. Science 294:1299-1304.
28. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365:2497-2506.
29. Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A, Woessmann W. 2004. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 18:584-588.
30. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, Group BFM. 2005. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 105:948-958.
31. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, Kim SJ, Kim WS, Lee S, Ko YH. 2014. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46:371-375.
32. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. 2013. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:1398-1403.
33. Zhang S, Zhou X, Lang RA, Guo F. 2012. RhoA of the Rho family small GTPases is essential for B lymphocyte development. PLoS One 7:e33773.
34. Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, Klitgord N, Tam S, Yu H, Venkatesan K, Mou D, Swearingen V, Yildirim MA, Yan H, Dricot A, Szeto D, Lin C, Hao T, Fan C, Milstein S, Dupuy D, Brasseur R, Hill DE, Cusick ME, Vidal M. 2009. Edgetic perturbation models of human inherited disorders. Mol Syst Biol 5:321.